Evidence map›Paper›PMID 36760814›Full record

ArticleFrontiers in endocrinology2022

Effects of

Yang Ping, Changxu Li, Lihong Wang, Hong Zhao

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Construction of microneedle ofFrontiers in endocrinology · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Yang PingCollege of Pharmacy, Jiamusi University, Jiamusi, Heilongjiang, China.
Changxu LiCollege of Pharmacy, Jiamusi University, Jiamusi, Heilongjiang, China.
Lihong WangCollege of Pharmacy, Jiamusi University, Jiamusi, Heilongjiang, China.
Hong ZhaoCollege of Pharmacy, Jiamusi University, Jiamusi, Heilongjiang, China.
Jiamusi University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In recent years, mammary gland hyperplasia (MGH) has been considered to be one of the diseases caused by endocrine disorders. It has been shown that diseases caused by endocrine disorders can be treated by regulating intestinal microbial. As a commonly used medicine in clinical practice, Materials and methods: Eighteen female SD rats were selected and randomly divided into three groups: blank control group (Con), model control group (Mod), and AMP group, six rats in each group. MGH rat models were established by estradiol-progesterone combination and treated with AMP gastric infusion. The levels of E Results: AMP has good therapeutic effects on MGH rats, decreasing estradiol (E Conclusion: AMP can improve the intestinal microbiological environment of MGH rats, maintain the microecological balance of intestinal microbial, and improve MGH symptoms.

Indexed as

AtractylodesGastrointestinal MicrobiomeAnimalsEstradiolFemaleHyperplasiaPolysaccharidesProgesteroneRatsRats, Sprague-DawleyRNA, Ribosomal, 16SEstradiolPolysaccharidesProgesteroneRNA, Ribosomal, 16SAtractylodes Macrocephala Rhizoma polysaccharideendocrine disordershigh-throughput sequencingintestinal microbialmammary gland hyperplasia

Identifiers

PMID36760814
PMCPMC9905829
OpenAlexW4317934650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.